- Home
- GILD vs CRWD Comparison
GILD vs CRWD Comparison
Compare GILD & CRWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GILD
- CRWD
- Stock Information
- Founded
- GILD 1987
- CRWD 2011
- Country
- GILD United States
- CRWD United States
- Employees
- GILD N/A
- CRWD N/A
- Industry
- GILD Biotechnology: Biological Products (No Diagnostic Substances)
- CRWD EDP Services
- Sector
- GILD Health Care
- CRWD Technology
- Exchange
- GILD Nasdaq
- CRWD Nasdaq
- Market Cap
- GILD 129.9B
- CRWD 109.4B
- IPO Year
- GILD 1992
- CRWD 2019
- Fundamental
- Price
- GILD $109.11
- CRWD $483.64
- Analyst Decision
- GILD Buy
- CRWD Buy
- Analyst Count
- GILD 25
- CRWD 47
- Target Price
- GILD $110.17
- CRWD $451.68
- AVG Volume (30 Days)
- GILD 7.8M
- CRWD 4.3M
- Earning Date
- GILD 08-07-2025
- CRWD 06-03-2025
- Dividend Yield
- GILD 2.93%
- CRWD N/A
- EPS Growth
- GILD 1118.07
- CRWD N/A
- EPS
- GILD 4.73
- CRWD N/A
- Revenue
- GILD $28,735,000,000.00
- CRWD $4,136,022,000.00
- Revenue This Year
- GILD $1.55
- CRWD $23.18
- Revenue Next Year
- GILD $3.69
- CRWD $21.48
- P/E Ratio
- GILD $22.83
- CRWD N/A
- Revenue Growth
- GILD 4.68
- CRWD 25.94
- 52 Week Low
- GILD $62.69
- CRWD $200.81
- 52 Week High
- GILD $119.96
- CRWD $493.20
- Technical
- Relative Strength Index (RSI)
- GILD 49.92
- CRWD 61.57
- Support Level
- GILD $107.19
- CRWD $474.00
- Resistance Level
- GILD $111.78
- CRWD $493.20
- Average True Range (ATR)
- GILD 2.77
- CRWD 14.35
- MACD
- GILD -0.44
- CRWD -0.57
- Stochastic Oscillator
- GILD 33.91
- CRWD 82.78
About GILD Gilead Sciences Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics).
About CRWD CrowdStrike Holdings Inc.
CrowdStrike is a cloud-based cybersecurity company specializing in next-generation security verticals such as endpoint, cloud workload, identity, and security operations. CrowdStrike's primary offering is its Falcon platform that offers a proverbial single pane of glass for an enterprise to detect and respond to security threats attacking its IT infrastructure. The Texas-based firm was founded in 2011 and went public in 2019.